Camlin Fine Sciences Increases Stake in Vinpai to 83.82% via Convertible Bond Conversion
Camlin Fine Sciences has increased its stake in Vinpai to 83.82% by converting EUR 33,00,000 in convertible bonds into 11,00,000 new ordinary shares. The transaction was completed on January 9, 2026. Vinpai, an ingredient'tech company, reported a turnover of €9.157 million in FY2024.
The increased shareholding in Vinpai strengthens Camlin Fine Sciences' position in the ingredient'tech market, which could lead to synergistic benefits and revenue growth, impacting the company's overall business trajectory.
The company has successfully increased its stake in Vinpai, indicating a positive development in its acquisition strategy and expansion into the ingredient'tech sector.
Camlin Fine Sciences Limited (CFS) has announced an update regarding its acquisition of Vinpai, a French société anonyme. Following the conversion of 3,300 Convertible Bonds, each with a subscription price of EUR 1,000, aggregating to EUR 33,00,000 (Euros Three Million Three Hundred Thousand), into 11,00,000 new ordinary shares of Vinpai, CFS has increased its shareholding. The transaction was completed on January 9, 2026, with the issuance and credit of these shares to CFS's demat account. These shares are slated for listing on Euronext Growth Paris.
Vinpai is an ingredient'tech company specializing in algae, plant, and mineral-based functional ingredients, offering natural alternatives to chemical additives for the food, cosmetics, and nutraceutical industries. In its financial year 2023 (January 2023 to December 2023), Vinpai generated a turnover of €7.9 million with a loss of €3.4 million after tax. For its financial year 2024, Vinpai reported a turnover of €9.157 million.
Following this conversion, Camlin Fine Sciences now holds a total of 38,23,316 ordinary shares in Vinpai, representing 83.82% of its outstanding share capital. This update is in continuation of CFS's previous intimations dated February 24, 2025, and November 30, 2025, concerning the acquisition of 78.68% of Vinpai's share capital through a share swap arrangement.
What to do with a filing like this
Camlin Fine Sciences Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Camlin Fine Sciences Limited. Read the original for the full detail.